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To identify novel causes of hereditary thrombocytopenia, we performed a genetic asso-
ciation analysis of whole-genome sequencing data from 13037 individuals enrolled in the
National Institute for Health Research (NIHR) BioResource, including 233 cases with iso-
lated thrombocytopenia. We found an association between rare variants in the tran-
scription factor-encoding gene IKZF5 and thrombocytopenia. We report 5 causal missense
variants in or near IKZF5 zinc fingers, of which 2 occurred de novo and 3 co-segregated in
3 pedigrees. A canonical DNA-zinc finger binding model predicts that 3 of the variants
alter DNA recognition. Expression studies showed that chromatin binding was disrupted
in mutant compared with wild-type IKZF5, and electron microscopy revealed a reduced
quantity of a granules in normally sized platelets. Proplatelet formation was reduced in
megakaryocytes from 7 cases relative to 6 controls. Comparison of RNA-sequencing data
from platelets, monocytes, neutrophils, and CD41 T cells from 3 cases and 14 healthy
controls showed 1194 differentially expressed genes in platelets but only 4 differentially
expressed genes in each of the other blood cell types. In conclusion, IKZF5 is a novel
transcriptional regulator of megakaryopoiesis and the eighth transcription factor associ-
ated with dominant thrombocytopenia in humans. (Blood. 2019;134(23):2070-2081)
Introduction
More than 30 genes have been implicated in hereditary throm-
bocytopenia,1 of which 7 genes encode lineage-specific tran-
scription factors (TFs).2 Variants in 2 of these genes (RUNX1 and
ETV6) increase the risk of leukemia,3,4 whereas others are associ-
ated with bone marrow failure (HOXA11 andMECOM), red blood
cell defects (GATA1 and GFI1B), or syndromic disorders (FLI1).5-8
IKZF5 (Pegasus) is 1 of the 5 members of the Ikaros family of
TF genes. IKZF1 through 3 (Ikaros, Helios, and Aiolos), have
established roles in lymphocyte development,9 with germline
mutations in IKZF1 implicated in common variable immunode-
ficiency and somatic variants in both IKZF1 and IKZF3 associated
with hematological malignancies.10-12 In contrast, the functions
of IKZF4 (Eos) and IKZF5, which are both widely expressed in
hematopoietic cells,13 have remained unknown. IKZF5 encodes
a DNA-binding factor that recognizes elements containing the
core sequence GNNTGTNG via its 3 N-terminal zinc fingers
(Znfs), whereas the C-terminal Znfs control self-association of
Ikaros proteins. IKZF5 is highly homologous to the other Ikaros
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proteins except at the N terminus, where it contains 3 rather than
4 Znfs and has distinct DNA-binding sites.14,15 Here, we present
genetic and functional evidence demonstrating that rare mis-
sense variants in IKZF5 cause thrombocytopenia.
Methods
Enrollment, research ethics, and consent
Enrollment of participants in the National Institute for Health
Research (NIHR) BioResource–Rare Diseases occurred between
December 2012 and March 2017. All participants provided
written informed consent either under the East of England
Cambridge South national research ethics committee reference
13/EE/0325 or alternate research ethics committee-approved
studies for UK patients; obtaining consent for overseas samples
was the responsibility of the respective principal investigator at
the enrolling hospitals following oversight of the consent form
for their study and a material transfer agreement.16
Clinical and laboratory phenotype data
We collected clinical data from probands and pedigree mem-
bers and coded themwith Human PhenotypeOntology terms as
described previously.17 Individuals with isolated thrombocyto-
penia were defined as those who had a Human Phenotype
Ontology term “thrombocytopenia” or a platelet count (PLT)
,1303 109/L and were deemed nonsyndromic (ie, did not have
any severe abnormalities in other organ systems).
DNA sequencing and variant calling
DNA extraction, library preparation for whole-genome se-
quencing (WGS) and whole-exome sequencing (WES), variant
calling, and variant annotation were performed as described
previously.16,17
Variant confirmation and cosegregation studies
Variants called by WGS were confirmed and tested for in
pedigree members by polymerase chain reaction (PCR) and
Sanger sequencing. Primers were designed with Primer3Plus
(https://primer3plus.com/cgi-bin/dev/primer3plus.cgi). Routine
PCR was performed using MyTaq HS Mix (BIOLINE BIO-25045),
a 23 Hot-start mix. Primers were used at a final concentration of
0.5 mM in 20-mL reactions. Thermal cycling using a Touchdown
protocol,18 with GeneAmp PCR System 9700 (Applied Bio-
systems, ThermoFisher). The Cycling protocol was an initial
denature step of 3 minutes at 95°C, then 15 cycles of 95°C for 30
seconds, 70°C 1-minute touchdown (1°C/cycle), and 72°C for
30 seconds. The final cycling phase was 25 cycles of 95°C for
30 seconds, 55°C for 1 minute, and 72°C for 30 seconds, with
a final extension of 72°C for 5 minutes. The PCR products were
checked by agarose gel electrophoresis, column purified using
QIAquick PCR Purification kit (QIAGEN catalog no. 28106) and
eluted with 30 mL nuclease free water. The amplicons were
quantified with QUBIT dsDNA BR assay kit (Life Technologies
Ltd [Invitrogen Division] catalog no. Q32853). Purified, quanti-
fied amplicons were sent to Source Bioscience for Sanger
sequencing, with the same primers that were used to amplify
the target. The primers used were 59-TCCAATGAATGGA
CAAGCAA-39 and 59-TCGAGAGCTGATTCAAAGGG-39, for
variants at GRCh37 positions 10:124754093, 10:124754138,
and 10:124754155, targeting a 530-bp amplicon. Variants
called by WES were confirmed and tested for in pedigree
members following a similar approach. The primers used were
59-TTTTGTGAGAAGTGAACTGTC-39 and 59-AGGGCATC
ACTTCTGACCTGT-39, for variants at GRCh37 positions
10:124755560 and 10:124755540, targeting a 491-bp amplicon.
Genetic association analysis
We applied BeviMed19 to compute a probability of association
between each gene and case/control status, defined by pres-
ence or absence of isolated thrombocytopenia, among un-
related individuals, as described previously.16 In general, we
excluded somatic short variants/indels with an allele count in any
GnomAD population in excess of what would be expected given
a true population minor allele frequency of 1/10 000 (under
a dominant model) or 1/1000 (under a recessive model).16 Large
deletions with an internal allele count among unrelated Euro-
peans or non-Europeans in excess of what would be expected
given a population allele frequency of 1/200 were also ex-
cluded.16 To boost power, when assessing the evidence for
genetic association with thrombocytopenia for a particular gene,
cases with explanatory variants in other genes were treated as
controls. Thus, the numbers of cases and controls varied slightly
by gene, depending on whether the gene being assessed
contained any cases carrying known pathogenic variants. Variant
selection on the basis of allele frequency and predicted con-
sequence was performed as described previously.16 BeviMed
compares the statistical support for a baseline model in which
disease risk is independent of the genotypes with various as-
sociation models in which disease risk depends on the allele
configuration at the given rare variant sites, a latent partition of
variants into pathogenic and benign groups, and a Mendelian
mode of inheritance. The association models are fitted to dif-
ferent subsets of variants in a given locus corresponding to
different predicted consequences, which imposes a prior cor-
relation structure on the pathogenicity of the variants that
reflects competing potential disease mechanisms.
Electron microscopy
We performed transmission electron microscopy (EM) analysis of
platelets as described previously.20 The platelet surface area (in
square micrometers) and the number of a granules per unit area
(in 1/mm2) were measured blinded to case/control status as done
previously for GATA1- and NBEAL2-related granule defects.21
Whole mount EM analysis to quantify dense granules was
performed as described previously.22
Megakaryocyte differentiation assays
CD341 hematopoietic stem cells (HSCs) were isolated by mag-
netic cell sorting (Miltenyi Biotec, Bergisch Gladback, Germany)
from peripheral blood. The recovered (differentiation day 0)
CD341 HSCs were cultured in StemSpan SFEM medium with
StemSpan CC100 ensuring expansion of HSC for 3 days (Stem
Cell Technologies, Vancouver, Canada). Liquid megakaryocyte
(MK) cultures were obtained by incubation with 50 ng/mL
thrombopoietin, 25 ng/mL stem cell factor, and 10 ng/mL in-
terleukin 1b (Peprotech, Rocky Hill, NJ). MKs were analyzed by
flow cytometry on total differentiation day 10 for CD41 and CD42
markers. Proplatelet formation (PPF) was quantified after immu-
nostaining of the cytoskeletal protein F-actin with phalloidin-
rhodamine (Sigma, St Louis, MO) and a granule marker von
Willebrand factor (VWF; A0082; Dako). For immunostaining, MKs
were seeded for 4 hours on fibrinogen-coated coverslips to allow
PPF; stained cells were photographed at 633 magnification
with a confocal microscope (AxioObserver Z1; Zeiss, Heidelberg,
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Figure 1. Rare missense variants in IKZF5 are associated with thrombocytopenia. (A) BeviMed was applied gene by gene to infer associations between the genotypes of
filtered rare variants and a case/control grouping defined by isolated thrombocytopenia. The posterior probabilities for genetic association inferred by BeviMed exceeding
0.4 are shown. The dots representing posterior probabilities for genes previously known to be implicated in hereditary thrombocytopenia are highlighted in blue. Genes not
previously associated with thrombocytopenia are in gray. (B) Evolutionary conservation scores with respect to 66 protein sequences obtained using multiple sequence
alignment within ConSurf,31 and the corresponding 95% confidence intervals, for amino acids (AAs) 1 through 419 of IKZF5, normalized to have a mean of 0 and standard
deviation of 1. The filled/empty points indicate presence/absence of missense variants in GnomAD altering the AAs. Only 3 of the 141 456 individuals in GnomAD harbor
a missense variant affecting a residue in the N-terminal Znfs with a normalized conservation score,21 (AAs 102, 111, and 123). The blue boxes indicate the locations of the Znfs.
The variants in cases with thrombocytopenia affecting the 5 conserved AAs have been followed up in cosegregation studies, while S200G, which affects a non-conserved AA, has
not been followed up. (C) Sex-stratified histograms of PLT obtained using a Sysmex hematology analyzer from 48 345 blood donors from the Efficiency and Safety of Varying the
Frequency of Whole Blood Donation study32 after adjustment for technical artifacts. The red arrows superimposed on the histograms indicate the sex of and values for cases
carrying 1 of the 5missense rare variants. The green arrows indicate the sex of and values for relatives homozygous for the correspondingWT allele. Individual C II.3, marked with
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Germany). PPF of MKs was assessed by random imaging of
40 MKs per condition.
Structural modeling
We modeled the functional consequences of the IKZF5 muta-
tions using the structural coordinates of Znf 4 of CCCTC-binding
factor (CTCF), the closest homolog of known structure to IKZF5
(PDB entry 5kkq). We did a BLAST search against the UniRef90
database23 to find unique relatives for the sequence covering
Znfs 1 to 3 of IKZF5 (residues 84-161). Structural consequences
of the mutations of this region of IKZF5 were evaluated in the
context of the closest homolog of known structure. We used
CCP4mg software24 to visualize the 3-dimensional structure of
IKZF5 domains
HEK293 expression and localization studies
We cloned wild-type (WT) and mutant IKZF5 in the pSecTag2/
HygroA vector (Life Sciences) to transfect HEK293 cells. We
prepared protein extracts 48 hours after transfection using the
subcellular protein fractionation kit for cultured cells (Thermo
Scientific) to isolate chromatin-bound proteins. We performed
western blotting using the following antibodies: rabbit poly-
clonal anti-IKZF5 (Atlas), rabbit monoclonal anti-glyceraldehyde-
3-phosphate dehydrogenase (clone 14C10; Cell Signaling) and
goat polyclonal anti-Histone H3 or HIST3H3 (clone C16; Santa
Cruz). We performed staining with the ECL detection reagent
(Life Technologies) and imaged chemiluminescent blots with the
ChemiDoc MP imager and the ImageLab software, version 4.1
(Bio-Rad). Transfected cells were analyzed with a confocal mi-
croscope (AxioObserver.Z1) and a structured illumination mi-
croscope (Elyra S.1; Zeiss) was used for z-stack images. Images
were analyzed with ZEN Black (Zeiss).
RNA-sequencing study
For each studied individual, we separated peripheral blood mono-
nuclear cells by gradient centrifugation (Percoll 1.078 g/mL)
and isolated neutrophils from the pellet after double red blood
cell lysis. Peripheral blood mononuclear cells were further
separated into monocytes by CD141 selection (Miltenyi) and
total CD4 (Stem Cell Technologies) from the CD14 column flow
through. Platelets were isolated from platelet-rich plasma after
leukocyte (CD451) depletion as described previously.25 All pro-
tocols used are available at http://www.blueprint-epigenome.
eu/. Purified cells were resuspended in Trizol, from which RNA
was extracted following the manufacturer’s instructions. For
each cell type, reverse transcription and preparation of a high-
throughput sequencing library was performed using the Riboerase
Kapa stranded RNA kit following the manufacturer’s instructions.
We generated 150-bp paired-end reads on an Illumina Hiseq4000.
We used TrimGalore, version 0.3.7 (http://www.bioinformatics.
babraham.ac.uk/projects/trim_galore/), with parameters “-q 15 -s
3 -length 30 -e 0.05” to trim PCR and sequencing adapters.
Trimmed reads were aligned to the Ensembl version 8026 human
transcriptome with Bowtie 1.0.127 using the parameters “-a -best
-strata -S -m 100 -X 500 -chunkmbs 256 -nofw -fr.” We used
MMSEQ (version 1.0.8a)28 with default parameters to quantify
gene expression. We inferred differential expression using
MMDIFF.29 Genes with a posterior probability (PP) of differen-
tially expression .0.8 were considered differentially expressed.
We performed Reactome pathway enrichment analysis using
the compareCluster and enrichPathway functions from the
ReactomePA Bioconductor R package.30
Results
Genetic analysis highlights IKZF5 as a candidate
gene for isolated thrombocytopenia
Using the BeviMed method for genetic association,19 for each
gene we compared the genotypes at rare variant sites of up
to 105 unrelated unexplained individuals having isolated
thrombocytopenia (cases) with the genotypes of up to 10053
unrelated individuals unaffected by thrombocytopenia or with
thrombocytopenia caused by variants in other genes (controls)
(see “Methods”). Of 33 814 genes assessed, 16 yielded a PP of
association .0.4, of which 13 are established genes implicated
in thrombocytopenia (Figure 1A). The associations for CSF3
and ELMOD1 were likely not causal because their high PPs
depended on variants absent from affected relatives of throm-
bocytopenic carriers being pathogenic. The BeviMed associa-
tion between thrombocytopenia and IKZF5 was driven by 4 rare
missense variants. We next reviewed an in-house dataset of
534 samples analyzed by WES from other individuals enrolled in
the NIHR BioResource, and identified 2 additional thrombocyto-
penic cases carrying 2 different rare missense variants in IKZF5. All
6 missense variants were absent from gnomAD and 5 variants,
encoding Y89C, R96W, G134E, C140R, and H155Y, were at
evolutionarily conserved residues located in or near the
N-terminal Znfs and were thus selected for further detailed
analysis, while a sixth missense variant, affecting residue 200
(S200G), was expected to be benign because it was located far
from Znfs and outside evolutionarily conserved regions
(Figure 1B).
Cosegregation studies showed that H155Y and C140R, in
pedigrees A and B, respectively (Figure 1D), occurred de novo,
with the latter appearing in monozygotic twins. Cosegregation
studies of G134E, Y89C, and R96W, in pedigrees C, D, and E,
respectively, identified 10 additional relatives carrying mutant
alleles and 2 unaffected relatives homozygous for the WT allele.
Only 2 of the 10 individuals carrying the mutant allele had PLT
.150 3 109/L: a father and son in pedigree C. Case C II.3
was a 53-year-old male with a PLT in adulthood of 253 3 109/L
who had undergone a splenectomy as a child for treatment of
thrombocytopenia. One of his sons (C III.1) had a PLT level of
183 3 109/L, which is in the 11.6th percentile of the PLT dis-
tribution for healthy males32 (Figure 1C; Table 1). Unfortunately,
he was not available to obtain a second PLT measurement or
for more detailed phenotyping. All other individuals who carried
the mutant IKZF5 allele across the 5 pedigrees had PLT,1503
109/L, with a normal platelet size (Table 1). Overall, 8 of 16 carriers
Figure 1 (continued) an asterisk, had thrombocytopenia as a child (with an unknownPLT) andwas subsequently splenectomized, likely explainingwhy his PLT increased to 2533
109/L as an adult. (D) The 5 pedigrees recalled for cosegregation.Male (square) and female (circle) individuals are shown in black or white depending onwhether they are affected
or unaffected, respectively, whereas individuals with an unknown PLT are shown in gray. Genotyping results obtained by WGS (G), WES (E), or Sanger sequencing (S) are shown in
terms of their predicted amino acid substitutions underneath the genotyped individuals. Crl, control; WT, homozygous for the reference allele. C III.4 carries the G134E variant
but has a PLT of 184.
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Table 1. Information on pedigree members






A I.1 M WT Sanger N 211 11.4
A I.2 F WT Sanger N 276 10.5
A II.1 M H155Y het* WGS Y 76 10.2 None Reduced Normal
A II.2 M WT Sanger N 193 10.8
B I.1 M WT Sanger N 173
B I.2 F WT Sanger N 301
B II.1 F C140R het* WGS Y 78 10.4 None TCP, all else
normal
Reduced Normal
B II.2 F C140R het* WGS Y 83 10.2 None TCP, all else
normal
Reduced Normal
B II.3 F WT Sanger N 257 10.9 Normal
C II.3 M G134E het WGS N 253† 12.5
C II.4 F WT Sanger N 327 11.4
C III.1 M G134E het Sanger Y 128 9.4
C III.3 F G134E het WGS Y 82 8.6 None TCP, all else
normal
C III.4 M G134E het Sanger N 184 11.1
C IV.1 M G134E het Sanger Y 82 8.8
D I.1 M N
D I.2 F Y
D II.2 F Y 110 8.2
D II.3 F Y89C het Sanger Y 97 8.9 Normal
D III.1 M N 195 9
D III.2 F Y89C het WES Y 70 8.3
E I.2 F Y
E II.1 M N 255
E II.2 M Y 155
E II.3 M R96W het WES Y 107 9.5 None Normal Reduced Normal
E II.4 F WT Sanger N 220 9
E II.6 M R96W het Sanger Y 111 10.4 None Normal Reduced Normal
E II.8 F R96W het Sanger Y 104 11 Mild Normal Reduced Normal
E III.1 F R96W het Sanger Y 96 8.9 None
E III.2 M R96W het Sanger Y 110 9.4 None
Blank entries are not known/not applicable.
BD, bleeding diathesis (none/mild/severe); F, female; het: heterozygous; M,male;MPV,most recentmean platelet volume;N, no; PLT, themean of PLTmeasurements is shownwheremultiple
counts had been obtained; TCP, thrombocytopenia; WT: homozygous for the reference allele; Y, yes.
*de novo mutation.
†PLT measured only after splenectomy to correct thrombocytopenia.
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(ie, 50%) had a PLT ,100 3 109/L and none had a PLT ,50 3
109/L. Because other members of the Ikaros family of Znf pro-
teins are critical for lymphoid development and are associated
with immune dysregulation and leukemia in humans, we spe-
cifically inquired about these features in the 5 pedigrees. No
leukemias were reported in any of the pedigrees and there were
no signs of immunodeficiency, such as recurrent infections.
Immunoglobulin levels were normal in all cases for whom they
were available (Table 1).
Platelets from IKZF5 cases are depleted of a and
dense granules and have an inconsistent
aggregation defect
Imaging by light microscopy of blood smears from the probands
of pedigrees A, B and E showed no structural abnormalities of
platelets and no visiblemorphological defects in other blood cell
types (Figure 2A; Table 1). Transmission EM analysis of platelets
from 7 cases and 5 unrelated controls showed that, in keeping
with previous measurements of mean platelet volume obtained
by hematology analyzers, the platelet size distributions of the
cases were normal (Figure 2B-C; Table 1). However, the platelets
of the cases were significantly depleted of a granules (Figure
2B,D) and they had empty vacuoles and empty membrane
structures (supplemental Figure 1, available on the Blood Web
site). Whole mount EM analysis revealed a small but significant
reduction in the number of dense granules per platelet in 2 cases
from pedigree E (supplemental Figure 2). We performed platelet
light transmission aggregometry (LTA) on the probands of
pedigrees B, C, D and E. LTA was completely normal in the cases
tested in pedigrees B and C but reduced in response to all
agonists in the probands of pedigrees D and E (supplemental
Table 1). 2 cases in pedigree E described mild bleeding symp-
toms but there was no significant bleeding history in any other
cases (Table 1). Pregnancies had occurred in 5 cases re-
sulting in 11 vaginal deliveries. No one required platelet sup-
plementation during pregnancy or delivery, although 1 case
(E II.8) required red cell transfusion for a postpartum hemorrhage
in 1 out of 3 deliveries (Table 1; supplemental Table 2).
Structural modeling of IKZF5 mutations
Although a crystal structure for IKZF5 (Pegasus) does not exist,
the sequence covering Znfs 4 through 7 of the human CCCTC-
binding factor CTCF33 is 45% identical to IKZF5 over the
78 residues from C84 to H161 and contains no insertions
or deletions. The relevant part of the bound DNA sequence in
this structure, AGCAGGGGGC, conforms to the pattern iden-
tified for sequences bound by the IKZF5/Pegasus family,
nGnnGnnnGn,14 so similar interactions with DNA are expected
to be conserved. We found a clear structural explanation for
deleterious effects for 3 of the 5 mutations: Y89C would disrupt
a binding contact with a backbone phosphate of the DNA;
C140R would remove the first ligand in the third Znf domain; and
R96W would disrupt a direct interaction with the penultimate
guanine base of the consensus sequence in the major groove
(Figure 3A). G134 is part of the most common consensus linker
sequence between consecutive Znfs (TGEKP35) and it may play
a role in flexibility during DNA recognition36 and as a recognition
site for threonine (or serine) phosphorylation during mitosis,37
so mutations here would be expected to alter function. Al-
though the structure of CTCF reveals no obvious reasons why
H155Y could not be accommodated, the surrounding sequence
SHHRRR is conserved in almost all of the top 50 hits from our
BLAST38 search, but is replaced by KMHILQ in CTCF, which
suggests that H155 may be important for interaction with the
remainder of IKZF5 or its binding partners. Our modeling thus
predicted alterations in Znf binding to DNA for at least 3 of the
variants, and we therefore expected alterations in cellular lo-
calization of IKZF5 in some of the mutants.
Abnormal nuclear localization and chromatin
binding in IKZF5 cases
To further investigate the effect of the IKZF5 variants on DNA
binding, we expressed the 5 causal mutants, the variant en-
coding S200G, a low-frequency variant (175 mutant alleles out
of 280 830 in gnomAD) encoding I98V in the third Znf domain
and WT IKZF5 in HEK293 cells, which do not express this
TF. In contrast to WT IKZF5, which enters the nucleus to bind to
Table 1. (continued)






E III.3 F Y 127 11
E III.4 M Y 135 8.8
E III.5 F Y 106 12
E III.6 M Y 140 11.9
E III.7 F R96W het Sanger Y 117 11.4 Mild Normal Reduced Normal
E III.9 M N 275
E IV.1 F Y 110
Blank entries are not known/not applicable.
BD, bleeding diathesis (none/mild/severe); F, female; het: heterozygous;M,male;MPV,most recentmean platelet volume;N, no; PLT, themean of PLTmeasurements is shownwheremultiple
counts had been obtained; TCP, thrombocytopenia; WT: homozygous for the reference allele; Y, yes.
*de novo mutation.
†PLT measured only after splenectomy to correct thrombocytopenia.
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chromatin, all 5 causal mutants exhibited a strong reduction in
chromatin binding (Figure 3B-D), remaining instead in the cy-
tosol and soluble membranes fractions (supplemental Figures 3
and 4). However, S200G and I98V entered the nucleus in
a similar manner to WT IKZF5, suggesting that only missense
substitutions of highly conserved residues in the N-terminal
Znfs may cause thrombocytopenia (Figure 3B-C; supplemental
Figure 3).
IKZF5 cases have abnormal PPF
Modeling and cellular localization studies of IKZF5 mutants
pointed to defective transcriptional regulation. Because thrombo-
cytopenia can be caused by alterations of TF activity during
megakaryopoiesis, we studied MK development in IKZF5 cases.
Microscopic evaluation of bone marrow aspirate smears from
B II.2, D III.3, E II.8, and E III.2 showed a normal number of
MKs without dysmegakaryopoiesis, which suggests normal ma-
turation and differentiation of the megakaryocytic lineage. No
abnormalities were present in the other lineages. We further
studied MK development using blood-derived HSCs. MK dif-
ferentiation evaluated by quantifying CD411 and CD42b1 cells
was comparable between subject E II.3 and 2 unrelated controls
(Figure 4A). However, PPF by MK in these cultures seemed
reduced for E II.3 compared with controls (Figure 4B). To further
characterize the PPF defect, we quantified PPF after MK
spreading on fibrinogen and staining with VWF and found it to
be significantly reduced in 7 cases from 3 pedigrees compared
with 6 unrelated healthy controls (P 5 .0069, linear mixed re-
gression model; Figure 4C). However, there was no discernible
difference in the number or spatial distribution of VWF1


















































Crl4 E II.8E II.3
B II.1
Figure 2. Cases have normally sized platelets but reduced numbers of a granules. (A) Representative May-Grünwald-Giemsa stained peripheral blood smear of
patient E II.3. Platelets have a normal appearance (size and granularity) by light microscopy (magnification 3100). (B) Representative EM images for 2 unrelated healthy
controls and 4 patients from pedigrees A, B, and E showing depletion of a granules. Marker is 1.5 mM for magnification x20 000. (C, D) The sizes and quantities of a granules
per unit area of 20 platelets, quantified blinded to case/control status, in each of 5 cases and 7 controls. Linear mixed model with a fixed effect for case/control
status, a random effect for pedigree (groupings in gray) and a random effect for sample. The P value under the null hypothesis that the fixed effect is equal to 0 is shown
for each of the 2 responses.














































































































Experiment 1 2 3 4 5 6
Figure 3. Structural modeling of the variants and expression studies in HEK293 cells. (A) Left panel: Mutation sites in Znf 1 of IKZF5. The structure of Znf 4 from CTCF (PDB
entry 5kkq33) is portrayed as a template to understand the effect of themutations Y89C (site equivalent to Y358) and R96W (site equivalent to K365). Tomodel the conformation of
R96, K365 in the CTCF structure was replaced by an arginine in a similar conformation to that of R369 in PDB entry 5kl6.34 WT side chains are shown in ball-and-stick rep-
resentation, whereas themutated side chains are shown as partially transparent cylinders. Right panel: The role of C140 in Znf 3.We used the coordinates for Znf 6 from PDB entry
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MK-specific transcriptional regulation if IKZF5
IKZF5 is expressed across hematopoietic lineages but IKZF5
cases have normal blood counts, except for thrombocytopenia.
To understand this, we performed RNA-sequencing on the CD41
T cells, monocytes, neutrophils, and platelets in 3 unrelated cases
from pedigrees A, B, and E and 14 unrelated controls. We gen-
erated a mean of 51.3M paired-end reads per sample (range,
24.2M-83.9M), of which we aligned a mean of 29.4M (range,
15.4M-53.1M) to the reference human transcriptome (supple-
mental Figure 6). Our analysis revealed striking differences in the
platelet transcriptome landscape only: 1194 protein-coding genes
of 10237 genes in Reactome39 were differentially expressed in
platelets but only 4 such genes were differentially expressed in
each of the 3 other cell types (Figure 5A). The 631 downregulated,
differentially expressed genes (DEGs) in platelets were significantly
enriched for pathways involved in platelet function, hemostasis,
and membrane and vesicle-mediated transport (Figure 5B),
whereas upregulated DEGs had more general functions (supple-
mental Table 3). The most significantly enriched pathway among
the downregulated DEGs was platelet activation, signaling and
aggregation, for which 52 of 262 (19.8%) genes were significantly
downregulated, including known disease-associated genes2 in-
volved in platelet formation (CDC42, GP1BA, GP9, MPIG6B) and
function (FERMT3, PLA2G4A, P2RY12, and TBXA2R) (Figure 5C).
Discussion
Rare variants in other genes cause a combination of thrombo-
cytopenia and a granule abnormalities. Rare variants in NBEAL2
can cause Gray platelet syndrome (GPS), an autosomal recessive
disease hallmarked by a complete absence of a granules and an
enlargement of platelets, in addition to thrombocytopenia.40,41
In the TF domain, GATA1 mutations cause a paucity of
a granules numbers and enlarged platelets,21 GFI1B mutations
cause a paucity of a granules and enlarged platelets,42 FLI1
mutations cause fused and enlarged a granules43 and RUNX1
mutations cause a granule storage and secretion defects.44 In-
terestingly, our RNA-sequencing analysis from platelets lacking
functional IKZF5 identified a striking platelet-specific defect,
which is consistent with the isolated thrombocytopenia seen
in the affected cases. Given the apparent lack of abnormalities
in any cell types other than platelets, this may be the first
TF-associated thrombocytopenia, which is completely lineage
specific.
Transcriptome analysis identified hundreds of DEGs related to
membrane and vesicle-mediated transport pathways, pointing
to a possible mechanism for the a granule defect. IKZF5-related
disorder does not appear to lead to a significant platelet function
defect, as shown by the lack of bleeding symptoms in the
majority of cases. Platelet function results obtained by light
transmission aggregometry were inconsistent among the cases,
with some having normal responses to all agonists. This vari-
ability is similar to that seen in other a granule defects such as
GPS45; however, further studies of platelet function are required
to understand the clinical implication, if any, of the observed
paucity of a granules. In contrast to GPS, there was no clini-
























































Figure 4. Reduced PPF inMKs from cases. (A) Flow cytometry analysis of day 10MK for markers CD41 and CD42 showed no difference in maturation between control and case
MKs. (B) The same cultures showed evidence of reduced PPF (arrows). (C) PPF was quantified after MK spreading on fibrinogen and staining for VWF for 6 unrelated controls and
7 cases. Linear mixed model with a fixed effect for case/control status, a random effect for pedigree and a random effect for sample. The P value under the null hypothesis in
which that the fixed effect is equal to 0 is shown.
Figure 3 (continued) 5kkq without any changes as all the side-chains shown are conserved between the 2 sequences. (B) Western blot analysis of HEK293 transfected cells with
myc-tagged IKZF5 WT and mutants after extraction of chromatin-bound proteins. HIST3H3 (histone H3) serves as loading control. HEK293 transfected with empty vector (Mock)
express no IKZF5. The 5 causal mutants are highlighted in red. (C) Quantification of chromatin-bound IKZF5 after transfections and normalization against HIST3H3. The 5 causal
mutants are highlighted in red. (D) Immunofluorescence (z-stack images by a structured illumination microscope) using an antibody against IKZF5 (green), phalloidin (actin; red),
and 49,6-diamidino-2-phenylindole (nucleus, blue) showing punctate, nuclear staining for WT IKZF5, whereas R96W and other mutants (supplemental Figure 4) remain largely
outside the nucleus after transfecting HEK293 cells. Scale bar, 10 mm.
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cytopenias, or morphological changes on the blood smear) in
any of the cases presented here and, unlike the other Ikaros
proteins, there is no evidence of lymphoid or immune dysre-
gulation. Therefore, based on the available evidence, throm-
bocytopenia resulting from rare missense variants in IKZF5,
is associated with a good prognosis, in sharp contrast with
thrombocytopenia from mutations in other TFs such as RUNX1
and ETV6. The reduction in PLT in IKZF5 cases is mild: none of
the PLTs in members of the 5 pedigrees were,703 109/L and 1
unrecallable carrier had a PLT as high as 184 3 109/L, reflecting
the complex regulation of megakaryopoiesis and the ensuing
variation in PLT in the normal population. However, there was no
evidence of alterations in mean platelet volume in IKZF5 cases
compared with their healthy relatives.
Heterozygous mutations in the DNA-binding Znf domains of
IKZF1 exert a dominant-negative effect,46,47 with interactions
between the WT and mutated DNA-binding domains resulting
in dimers that lack transcriptional activity.48 We propose that
the mechanism through which the heterozygous variants in IKZF5
exert their effect is similar. We have shown that the IKZF5
variants cause abnormal cellular localization and decreased
chromatin binding in HEK293T cells and, in vivo, this would be
expected to affect transcription. The discovery of rare missense
variants in the N-terminal Znf domains of IKZF5 as a novel cause
of inherited thrombocytopenia highlights an important role
for this previously unknown TF in megakaryocyte and platelet
biology.
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Figure 5. IKZF5 deficiency misregulates transcription in MKs. (A) Barplot of the number of up- and downregulated Reactome/Ensembl coding genes in CD41 T cells,
monocytes, neutrophils, and platelets that are differentially expressed between 14 unrelated controls and 3 unrelated cases. (B) Enriched downregulated pathways in platelets
with P, 1025. The number of downregulated, upregulated, and nondifferentially expressed genes in each pathway are shown in brackets. (D) Heatmap of expression for genes in
the “platelet activation, signaling, and aggregation” Reactome pathway. The expression levels have been row-normalized such that the color represents the log FC of
expression between samples and the mean log expression weighted by the number of cases and controls. The cases are on the left-most 3 columns and the controls are on the
right-most 14 columns. The PP of association is shown to the left of the heatmap and the significantly down- (blue) and upregulated (yellow) genes are shown to the right of the
heatmap. The significantly downregulated genes are listed in blue. FC, fold change.
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